GO:0140952 histone H3K27 dimethyltransferase activity

Histone H3K27 dimethyltransferase activity (GO:0140952) is a molecular function that catalyzes the addition of two methyl groups to lysine 27 of histone H3, yielding the dimethylated mark H3K27me2. This activity is a critical step in the Polycomb-mediated epigenetic silencing pathway, which controls developmental gene expression programs and cell fate decisions. The enzyme responsible for this activity in humans is primarily EZH2, the catalytic subunit of Polycomb repressive complex 2 (PRC2), which utilizes S-adenosyl-L-methionine (SAM) as the methyl donor. Researchers study GO:0140952 because H3K27me2 is a dynamic mark that serves as both a precursor to the repressive H3K27me3 mark and a distinct epigenetic signal associated with poised or silenced chromatin states. The balance between methylation and demethylation at H3K27 is regulated by opposing enzymes, including the demethylases JMJD3 (KDM6B) and UTX (KDM6A), which remove methyl groups and can reverse silencing. Disruption of this balance has been linked to aberrant gene expression in cancer, liver disease, and other pathologies. Understanding the enzymatic mechanism, regulation, and disease relevance of H3K27 dimethyltransferase activity requires integrated approaches including CRISPR-based genome editing, biochemical assays, and next-generation sequencing. This article provides a research-grade overview of GO:0140952, covering its definition, biological roles, key genes, regulatory mechanisms, disease associations, and experimental models for functional studies.

GO:0140952, histone H3K27 dimethyltransferase activity, is defined as the catalysis of the reaction: L-lysyl27-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl27-[histone H3] + 2 S-adenosyl-L-homocysteine. This reaction represents the successive addition of two methyl groups to the unmethylated lysine residue at position 27 of histone H3, producing histone H3K27me2. The activity is synonymous with histone H3-K27 dimethylase activity, histone H3K27 dimethylase activity, histone H3-K27 dimethylation, histone H3K27 dimethylation, histone H3K27 mono/dimethylase activity, and histone lysine N-dimethyltransferase activity (H3-K27 specific).

Histone H3K27 dimethyltransferase activity is central to epigenetic regulation because it generates H3K27me2, a repressive chromatin mark that influences gene silencing, developmental timing, and cell identity. This activity is a key step in the Polycomb pathway, and its dysregulation can lead to inappropriate silencing of tumor suppressors or activation of oncogenes, contributing to cancer and other diseases. Moreover, the reversibility of H3K27 methylation by demethylases such as JMJD3 and UTX makes this activity a dynamic node for therapeutic intervention. Understanding GO:0140952 is therefore essential for researchers investigating epigenetic mechanisms, disease etiology, and potential targeted therapies.

The following genes encode proteins directly involved in histone H3K27 dimethyltransferase activity, its regulation, or the reversal of its product.

Histone H3K27 dimethyltransferase activity is regulated at multiple levels. The catalytic activity of EZH2 within PRC2 is stimulated by the binding of EED to H3K27me3, creating a positive feedback loop that propagates methylation. Accessory proteins such as JARID2, AEBP2, PHF1, and PHF19 modulate PRC2 targeting and enzymatic efficiency. Opposing demethylases JMJD3 and UTX remove methyl groups, thereby dynamically balancing H3K27me2 levels. Additionally, metabolic availability of SAM and accumulation of SAH can influence methyltransferase activity, linking cellular metabolism to epigenetic state. In disease contexts, EZH2 expression and activity are often dysregulated, leading to altered H3K27me2 patterns.

Dysregulation of H3K27 dimethyltransferase activity is frequently observed in cancers, where overexpression or gain-of-function mutations in EZH2 lead to aberrant H3K27me2/me3 and silencing of tumor suppressor genes. Conversely, loss-of-function mutations in UTX or JMJD3 can shift the balance toward hypermethylation, promoting oncogenesis. Targeting EZH2 with small-molecule inhibitors has emerged as a therapeutic strategy in lymphomas and other malignancies.

EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity, influencing retro-differentiation and proliferation of liver cells. Altered H3K27 methylation states contribute to liver regeneration, fibrosis, and hepatocellular carcinoma progression. Experimental modulation of these enzymes in liver models has demonstrated their causal role in controlling cell fate.

Mutations in PRC2 components or H3K27me2/me3 regulators can disrupt developmental gene expression programs, leading to congenital anomalies and neurodevelopmental disorders. The precise balance of H3K27 methylation is critical for proper differentiation and organogenesis.

ChIP-seq using antibodies specific for H3K27me2 allows genome-wide mapping of this mark and identification of target genes regulated by GO:0140952. This method is essential for understanding how EZH2 and demethylases shape the epigenetic landscape.

Western blot with anti-H3K27me2 antibodies quantifies global changes in dimethylation levels upon genetic or pharmacological perturbation. Immunofluorescence can visualize nuclear distribution of H3K27me2 in single cells.

CRISPR-Cas9 knockout, point mutation, knock-in, and overexpression models enable precise dissection of gene function in the H3K27 methylation pathway. These models are used to test causality between specific mutations and altered H3K27me2 levels.

RNA-seq measures transcriptomic changes following manipulation of H3K27 dimethyltransferase activity, revealing downstream gene expression programs. Combining RNA-seq with ChIP-seq links H3K27me2 marks to transcriptional outcomes.

Researchers studying histone H3K27 dimethyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in establishing or maintaining H3K27me2 marks. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such functional studies.

Histone H3K27 dimethyltransferase activity (GO:0140952) is a fundamental epigenetic function that generates the repressive H3K27me2 mark through the action of EZH2 and PRC2. Its dynamic regulation by demethylases and its role in development and disease make it a critical area of research. CRISPR-based models provide powerful tools to dissect the causal roles of this activity in health and disease. EDITGENE offers comprehensive services to support researchers in generating knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics, to advance the understanding of H3K27 methylation biology.